Entasis Therapeutics

73 articles about Entasis Therapeutics

• Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

  6/18/2021

  Entasis Therapeutics Holdings Inc. today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24.

• 

  GSK Sells Innoviva Shares Back to Respiratory Partner for $392 Million

  5/21/2021

  GSK said the sale of Innovia stock would help GSK invest in other “strategic priorities,” likely those aimed at plans to separate into two main offerings over the next couple of years.

• Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

  5/5/2021

  ATTACK Phase 3 topline data readout remains on track for second half of 2021

• Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.

  1/26/2021

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for U.S. patients with Acinetobacter

• Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

  1/7/2021

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company’s presentation will be available on demand starting Monday, January 11

• Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium

  11/17/2020

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19 th , 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with C

• Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update

  11/5/2020

  Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter 2020 financial results and provided a business update.

• Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week

  10/14/2020

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020. The details of the poster presentations include: “ Sulbactam- durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter

• Entasis Therapeutics Announces $25 Million Private Placement Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial

  8/31/2020

  Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today it has entered into a definitive agreement to sell securities in a private placement with Innoviva, Inc

• Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update

  8/6/2020

  Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its second quarter 2020 financial results and provided a business update.

• Entasis Therapeutics to Participate in Upcoming Healthcare Conferences

  8/5/2020

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11 th at 11:30am ET and at the Canaccord Genuity 40 th Annual Growth Conference on We

• Entasis Therapeutics Awarded Contract from National Institutes of Health

  7/6/2020

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced it has entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The initial award of approximately $3 million, with the potential to increase up to $15.5 million, will be used

• Entasis Therapeutics to Participate in the BMO 2020 Prescriptions for Success Healthcare Conference

  6/18/2020

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference being held virtually on June 23, 2020. Details of the fireside chat are below: Event:

• Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva

  6/11/2020

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the closing of the second tranche of the $35 million common stock and warrant investment by Innoviva, Inc. (NASDAQ: INVA) ("Innoviva"), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, under a

• Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update

  5/7/2020

  Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its first quarter 2020 financial results and provided a business update.

• Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update

  3/11/2020

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full year 2019 financial results and business highlights.

• Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical OfficerDr. Robin Isaacs to Retire at the End of the Year

  10/30/2019

  Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, announced the appointment of David Altarac, M.D., MPA as Chief Medical Officer, effective November 4, 2019.

• Entasis Therapeutics to Present at the 28th Annual Credit Suisse Healthcare Conference

  10/29/2019

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Michael Gutch, Chief Business Officer and Chief Financial Officer, will be hosting a fireside chat at the 28th Annual Credit Suisse Healthcare Conference being held November 11-13, 2019 in Scottsdale, AZ.

• Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019

  6/27/2019

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations of its innovative programs including sulbactam-durlobactam (ETX2514SUL), zoliflodacin and ETX0282CPDP, during the American Society for Microbiology (ASM) Microbe Conference 2019

• Entasis Therapeutics Announces Initial ETX0282 Phase 1 Results

  6/14/2019

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug-resistant infections, today reported initial preliminary results from the first-in-human Phase 1 clinical trial of its novel, oral beta-lactamase inhibitor ETX0282.